JPWO2022102457A1 - - Google Patents

Info

Publication number
JPWO2022102457A1
JPWO2022102457A1 JP2022561834A JP2022561834A JPWO2022102457A1 JP WO2022102457 A1 JPWO2022102457 A1 JP WO2022102457A1 JP 2022561834 A JP2022561834 A JP 2022561834A JP 2022561834 A JP2022561834 A JP 2022561834A JP WO2022102457 A1 JPWO2022102457 A1 JP WO2022102457A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561834A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022102457A1 publication Critical patent/JPWO2022102457A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
JP2022561834A 2020-11-10 2021-11-01 Pending JPWO2022102457A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020187106 2020-11-10
PCT/JP2021/040258 WO2022102457A1 (fr) 2020-11-10 2021-11-01 Comprimé à désintégration orale contenant de la linagliptine

Publications (1)

Publication Number Publication Date
JPWO2022102457A1 true JPWO2022102457A1 (fr) 2022-05-19

Family

ID=81602200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561834A Pending JPWO2022102457A1 (fr) 2020-11-10 2021-11-01

Country Status (2)

Country Link
JP (1) JPWO2022102457A1 (fr)
WO (1) WO2022102457A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7210794B2 (ja) * 2021-06-16 2023-01-23 日本ジェネリック株式会社 リナグリプチン含有製剤及びリナグリプチン含有口腔内崩壊性錠剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN02029A (fr) * 2012-04-24 2015-08-14 Daiichi Sankyo Companyltd
EP2848242A1 (fr) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations orodispersibles de Linagliptin
EP3359136A1 (fr) * 2015-10-09 2018-08-15 Hexal AG Composition pharmaceutique contenant de la 8-[(3r)-3-amino-1-pipéridinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-méthyl-1-[4-méthyl-2-quinazolinyl)méthyl]-1h-purine-2,6-dione ou son sel pharmaceutiquement acceptable
CN105853382B (zh) * 2016-05-19 2019-07-19 广州迈达康医药科技有限公司 一种利格列汀口崩片及其制备方法
JP7245694B2 (ja) * 2019-03-26 2023-03-24 エルメッド株式会社 リナグリプチン含有医薬組成物及びその製造方法、並びにリナグリプチン含有医薬組成物の品質の向上方法

Also Published As

Publication number Publication date
WO2022102457A1 (fr) 2022-05-19

Similar Documents

Publication Publication Date Title
BR112023005462A2 (fr)
BR112021014123A2 (fr)
BR112023012656A2 (fr)
BR112022024743A2 (fr)
BR112022009896A2 (fr)
BR102021007058A2 (fr)
BR102020022030A2 (fr)
BR112023011738A2 (fr)
BR112023016292A2 (fr)
BR112023004146A2 (fr)
BR112023011610A2 (fr)
BR112023011539A2 (fr)
BR112023008976A2 (fr)
BR112023006729A2 (fr)
BR102021015450A8 (fr)
BR102021015220A2 (fr)
BR102021015247A2 (fr)
BR102021014044A2 (fr)
BR102021014056A2 (fr)
BR102021013929A2 (fr)
BR112021017747A2 (fr)
BR102021012571A2 (fr)
BR102021012230A2 (fr)
BR102021012003A2 (fr)
BR102021012107A2 (fr)